300 Chapter 12 References 1. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017/04/25. 2017;17:407–20. 2. Angus DC, Bindman AB. Achieving Diagnostic Excellence for Sepsis. JAMA. United States; 2022;327:117–8. 3. Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. England; 2024;28:183. 4. Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz J V, Finfer S, et al. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU. Am J Respir Crit Care Med. United States; 2024;210:155–66. 5. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. England; 2019;5:66. 6. van Engelen TSR, Wiersinga WJ, Scicluna BP, van der Poll T. Biomarkers in Sepsis. Crit Care Clin [Internet]. 2018;34:139–52. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/29149935 7. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. 8. Brands X, de Vries FMC, Uhel F, Haak BW, Peters-Sengers H, Schuurman AR, et al. Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia. Crit Care Med. United States; 2021;49:1901–11. 9. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752– 60. 10. Papamanoli A, Kalogeropoulos AP, Hotelling J, Yoo J, Grewal P, Predun W, et al. Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia. JAMA Netw open. 2021;4:e2127172. 11. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. England; 2018;14:121–37. 12. Torres LK, Pickkers P, van der Poll T. Sepsis-Induced Immunosuppression. Annu Rev Physiol. United States; 2022;84:157–81. 13. van Vught LA, Wiewel MA, Hoogendijk AJ, Frencken JF, Scicluna BP, Klein Klouwenberg PMC, et al. The Host Response in Patients with Sepsis Developing Intensive Care Unitacquired Secondary Infections. Am J Respir Crit Care Med. United States; 2017;196:458–70. 14. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. England; 2016;8:39. 15. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science (80- ) [Internet]. 2016/04/30. 2016;352:544–5. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/27126037 16. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med [Internet]. 2010/01/19. 2010;16:228–31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20081863 17. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol [Internet]. 2016/11/01. 2017;15:55–63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27694885 18. Merriam-Webster Dictionary [Internet]. [cited 2024 Jul 12]. Available from: https://www. merriam-webster.com/dictionary/diagnosis
RkJQdWJsaXNoZXIy MTk4NDMw